Core Viewpoint - Southbound funds have significantly increased their holdings in MicroPort Medical (00853.HK), indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Southbound Fund Activity - On January 23, southbound funds increased their holdings by 1.6216 million shares of MicroPort Medical [1] - Over the past five trading days, there have been four days of net increases, totaling 7.5492 million shares [1] - In the last 20 trading days, there were 16 days of net increases, amounting to 33.0996 million shares [1] - Currently, southbound funds hold 913 million shares of MicroPort Medical, representing a significant portion of the company's issued ordinary shares [1] Group 2: Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 3.5917 million shares on January 22, 2026, marking a positive trend in investment interest [1] - Over the past five trading days, southbound funds have increased their holdings on four occasions, with a total net increase of 10.374 million shares [1] - In the last twenty trading days, there have been fifteen days of net increases in holdings, totaling 31.3323 million shares [1] Group 2 - As of January 22, 2026, southbound funds hold a total of 911 million shares of MicroPort Medical, which represents a significant portion of the company's issued ordinary shares [1] - The daily changes in shareholding for the last five trading days show fluctuations, with the largest increase being 4.4877 million shares on January 19, 2026, and a decrease of 2.0648 million shares on January 20, 2026 [2] - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices, operating through eight business segments including cardiovascular intervention, orthopedic medical devices, and surgical robotics [2]

Core Viewpoint - Southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 3.4078 million shares on January 8, 2026, indicating a positive trend in investor sentiment towards the company [1]. Group 1: Shareholding Changes - Over the past five trading days, Southbound funds have increased their holdings for five days, with a total net increase of 20.3882 million shares [1]. - In the last twenty trading days, there were seven days of net reduction in holdings, totaling 442,100 shares [1]. - As of now, Southbound funds hold 904 million shares of MicroPort Medical, accounting for 47.24% of the company's total issued ordinary shares [1]. Group 2: Shareholding Data - On January 8, 2026, the total number of shares held was 904 million, with a change of 3.4078 million shares, reflecting a 0.38% increase [2]. - On January 7, 2026, the total number of shares held was 901 million, with a change of 2.0976 million shares, reflecting a 0.23% increase [2]. - On January 5, 2026, the total number of shares held was 898 million, with a change of 3.3146 million shares, reflecting a 0.37% increase [2]. - On January 2, 2026, the total number of shares held was 2,556.8 million, with a change of 9.0958 million shares, reflecting a 1.03% increase [2]. - On December 30, 2025, the total number of shares held was 886 million, with a change of 2.4725 million shares, reflecting a 0.28% increase [2]. Group 3: Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices, operating through eight divisions [2]. - The cardiovascular intervention division includes products such as implantable devices and access devices [2]. - The orthopedic medical device division includes instruments for joint reconstruction and spinal applications [2]. - The cardiac rhythm management (CRM) division includes devices such as pacemakers and defibrillators [2]. - The aortic and peripheral vascular intervention division includes products like the "L-REBOA" aortic occlusion balloon [2]. - The neuro-intervention division includes products for treating cerebral artery atherosclerosis and coils [2]. - The structural heart disease division includes products for transcatheter aortic valve implantation [2]. - The surgical robotics division is involved in the manufacturing and R&D of surgical robotic instruments [2]. - The surgical medical device division focuses on the manufacturing and R&D of surgical medical devices [2].

Group 1 - The core point of the article is that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 3.31 million shares on January 5, 2026, with a total net increase of 16.43 million shares over the past five trading days [1] - Over the last 20 trading days, there were 7 days of net reductions in holdings, totaling 1.05 million shares [1] - As of now, southbound funds hold 899 million shares of MicroPort Medical, accounting for 46.96% of the company's total issued ordinary shares [1] Group 2 - The total number of shares held by southbound funds on January 5, 2026, was 899 million, reflecting a change of 3.31 million shares, which is a 0.37% increase [2] - The previous trading days showed significant changes, with an increase of 9.10 million shares (1.03%) on January 2, 2026, and smaller increases on December 30, 2025 (0.28%), December 29, 2025 (0.16%), and December 23, 2025 (0.02%) [2] - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices, operating through eight divisions including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, and surgical robotics [2]

Core Insights - Boston Scientific showcased 13 innovative minimally invasive products at the Import Expo, focusing on common diseases such as atrial fibrillation, stroke prevention, heart failure, carotid artery stenosis, obesity, benign prostatic hyperplasia, tumors, and Parkinson's disease [1][2] - The FARAWAVE NAV catheter, recently approved, was highlighted as a key product, along with other innovative solutions tailored to the needs of elderly patients in China [2][3] Group 1: Innovative Products - The company introduced several breakthrough therapies, including the SENTINEL embolic protection device for TAVR procedures, the ENROUTE device for carotid artery reconstruction, and the TheraSphere Y90 glass microsphere system for primary liver cancer treatment [3] - Additionally, Boston Scientific presented two weight management technologies, the Orbera365 gastric balloon system and the OverStitch endoscopic suturing device, addressing various obesity treatment needs [3] Group 2: Health Education and Community Engagement - Boston Scientific has invested in health promotion and community engagement, enhancing public health literacy and supporting medical talent development through various initiatives [4] - The company showcased three major public welfare segments at the expo, including a Zhihu science popularization area, patient story documentaries, and an exhibition of public welfare project outcomes [4] Group 3: Future Goals - Leveraging the Import Expo platform, Boston Scientific aims to amplify the outreach of advanced health concepts to a broader audience, contributing to the goal of a healthier China [5]

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 310,000 shares on December 9, with a total net increase of 5.3182 million shares over the last five trading days [1] - Over the past 20 trading days, there were 15 days of net increases, totaling 14.1728 million shares [1] - As of now, southbound funds hold 907 million shares of MicroPort Medical, accounting for 47.42% of the company's total issued ordinary shares [1] Company Overview - MicroPort Medical Science Co., Ltd. is primarily engaged in the sales, production, research, and development (R&D) of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business: Products include implantable devices and access devices [1] - Orthopedic Medical Devices: Focuses on joint reconstruction and spinal instruments [1] - Cardiac Rhythm Management (CRM): Involves pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business: Includes products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business: Products for treating cerebral artery atherosclerosis and coils [1] - Structural Heart Disease Business: Involves transcatheter aortic valve implantation [1] - Surgical Robotics Business: Engaged in the manufacturing and R&D of surgical robotic devices [1] - Surgical Medical Devices: Focuses on the manufacturing and R&D of surgical medical instruments [1]

转自：中国经营报 中经记者 陈婷 赵毅 深圳报道 一场作价6.8亿美元的并购，即将以"零现金"交易的形式展开…… 近日，心通医疗（2160.HK）正式公告收购微创心律管理有限公司（以下简称"心律管理"）100%股权， 对价为6.8亿美元（约合人民币48亿元），心通医疗通过向心律管理股东发行新股支付，即不涉及任何 现金交易。新股发行数量约39.54亿股，相当于心通医疗已发行股本约164%，价格为每股1.35港元。 这是一次关联交易。心通医疗、心律管理的控股股东均是微创医疗（0853.HK），且这两家公司目前均 处于亏损状态。其中，心通医疗在今年上半年亏损约人民币220万元，心律管理亏损4162万美元（约合 人民币近3亿元）。 此次交易的时间节点耐人寻味。4年前，微创医疗为心律管理引入投资机构，彼时约定若心律管理未能 在2025年7月17日前上市，或上市时市值少于15亿美元且募资额低于1.5亿美元，心律管理将面临赎回风 险。2023年5月，心律管理曾向港交所递交招股书谋求上市，但至今无果。就在上述约定心律管理上市 期限前1天，微创医疗宣布拟重组心律管理业务，将其与心通医疗合并。 此次并购是否为化解微创医疗对赌协议 ...

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 2.36 million shares on December 3, 2025, marking a total net increase of 10.81 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have increased their holdings on 12 occasions, resulting in a cumulative net increase of 8.71 million shares [1] - As of now, southbound funds hold 904 million shares of MicroPort Medical, accounting for 47.27% of the company's total issued ordinary shares [1] Summary by Category Shareholding Changes - On December 3, 2025, total shares held reached 904 million, with a change of 2.36 million shares, representing a 0.26% increase [2] - On December 2, 2025, total shares held were 902 million, with a change of 2.54 million shares, representing a 0.28% increase [2] - On December 1, 2025, total shares held were 276.68 million, with a change of 361,100 shares, representing a 0.04% increase [2] - On November 28, 2025, total shares held were 266.8 million, with a change of 1.55 million shares, representing a 0.17% increase [2] - On November 27, 2025, total shares held were 898 million, with a change of 4 million shares, representing a 0.45% increase [2] Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [2] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, large artery and peripheral vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [2]

Industry Overview - In 2024, China's medical device industry market size is projected to reach 1.2 trillion yuan, with medical equipment accounting for 55% of the market [2] - The first half of 2025 saw the approval of 45 innovative medical devices by the National Medical Products Administration, representing a year-on-year growth of 87% [2] Market Dynamics - The demand for innovative medical devices is driven by clinical needs, influenced by factors such as an aging population, the decentralization of medical resources, and large-scale updates of medical equipment [3] - National policies are promoting the development of high-end medical devices, accelerating innovation in domestic medical equipment [3] Technological Advancements - The integration of AI and digital technologies is transforming the medical device sector, leading to trends such as agile development and software-defined medical devices [3][4] - The release of the announcement by the National Medical Products Administration on July 3 supports the innovation of high-end medical devices through optimized approval processes and standard systems [3] Regulatory Environment - The medical device industry is characterized by strong regulatory oversight, necessitating rapid product development and innovation to meet market demands [4] - The concept of Regulated Software Lifecycle Management (RSLM) is gaining traction, emphasizing the management of software products embedded in critical medical devices [4] Company Spotlight: PTC Codebeamer - PTC Codebeamer is recognized as a leader in the ALM software space, facilitating compliance with stringent regulations while accelerating innovation in medical devices [4][6] - The platform supports agile software development and integrates with top DevOps and source code management tools, enhancing collaboration and efficiency [5][7] - PTC Codebeamer 3.0, released in April 2025, ensures comprehensive traceability across product development, helping companies mitigate compliance risks [6]

Core Viewpoint - The 2024 Annual Report on Adverse Events Monitoring of Medical Devices indicates a significant increase in reported adverse events, reflecting improved regulatory oversight and risk management capabilities in China's medical device sector [1][2]. Group 1: Report Statistics - A total of 946,200 adverse event reports were received in 2024, representing a 9.11% increase from the previous year [2]. - The average number of adverse event reports per million population reached 671, also a 9.11% increase year-on-year [2]. - The majority of reports came from usage units, accounting for 849,600 reports (89.79%), followed by business enterprises with 67,200 reports (7.11%) and registrants with 29,000 reports (3.06%) [2]. Group 2: Classification of Medical Devices - Reports related to Class III medical devices totaled 379,200 (40.08%), Class II devices accounted for 482,900 (51.04%), and Class I devices made up 69,900 (7.39%) [3]. - The top five categories of reported adverse events included infusion, nursing and protective devices, medical examination and monitoring devices, clinical testing devices, and respiratory, anesthesia, and emergency devices [3]. Group 3: Monitoring and Evaluation Enhancements - The National Center for Adverse Drug Reaction Monitoring has improved its risk signal coordination mechanism, ensuring timely detection and effective management of product risks [4]. - In 2024, 12 issues of the "Medical Device Alert Bulletin" were published, summarizing 78 safety information items from international regulatory agencies, aiding in domestic safety evaluations [4]. Group 4: Collaborative Efforts and Standards Development - The report highlights advancements in the collaborative governance mechanism among regulatory departments, monitoring institutions, registrants, and medical institutions, enhancing the medical device vigilance system [5]. - The development of new technical documents, including the "Quality Management Specification for Medical Device Vigilance (Trial Version)," has been initiated, contributing to the establishment of a robust vigilance system [5]. Group 5: International Cooperation - The National Center for Adverse Drug Reaction Monitoring actively participated in international forums and information exchange initiatives, promoting global cooperation in medical device adverse event monitoring [6].